Just_Super/iStock via Getty Images Medtronic PLC (NYSE:MDT) is a global developer and manufacturer of medical devices for chronic diseases. Founded in 1949, Medtronic is now a $111 billion (by market cap) healthcare behemoth that employs 95,000 people. The company reports results across four segments: Cardiovascular, 37% of FY 2023 revenue; Neuroscience, 29%; Medical Surgical, 27%; and Diabetes, 7%. Medtronic’s product portfolio is comprised of a variety of life-saving and life-improving medical devices ...

Medtronic plc (MDT) recently presented a set of new clinical and real-world evidence on the MiniMed 780G system from around the world. The latest data reveals that the system withstands strong global performance, exceeding international targets for diabetes management.The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.Study DetailsAccording to the business, the findings are built on three years of data published in Diabe ...

Key PointsMedtronic is a leading medical device maker known for inventing the world's first portable and implantable pacemaker.Medtronic is a Dividend Aristocrat that's consistently raised its dividend payments for 46 consecutive years.Medtronic beat its fiscal Q3 2024 EPS by 15 cents, grew revenues by 4.7% YoY and raised its fiscal full-year 2024 guidance along with adding $5 billion to its stock buyback program.5 stocks we like better than MedtronicMedical device maker Medtronic PLC NYSE: MDT is a Dividen ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measuresDUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th Internatio ...

Board authorizes $5 billion for share repurchases DUBLIN, March 7, 2024  /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past ...

Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no significant changes in stroke volume or contractility. AVIM therapy showed consistent favorable hemodynamic effects using both conduction system pacing, as well as traditional rig ...

Rising tides don't always lift all boats. The S&P 500 index reached new all-time highs several times since 2024 began, but many of its components have not participated in the rally.With most investors focusing all their attention on the artificial intelligence (AI) revolution, plenty of reliable dividend payers aren't getting the attention they deserve. Since peaking in 2021, shares of Medtronic (MDT 1.75%) are down about 38% and poised for a rebound. Altria Group (MO -2.77%) and Realty Income (O 0.90%) hit ...

This photo taken on Nov. 8, 2023 shows a booth of Medtronic at the 6th China International Import ... [+] Expo CIIE in east China's Shanghai. (Photo by Wang Xiang/Xinhua via Getty Images)Xinhua News Agency via Getty ImagesMedtronic MDT (NYSE: MDT) recently reported its Q3 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating the street estimates. The company reported revenue of $8.1 billion and adjusted earnings of $1.30 per share compared to the consensus estimates of $7.9 billion ...

公司财务状况 - 2024年1月26日，梅德特公司净利润为13.37亿美元，较上年同期增长8.8%[6] - 2024年1月26日，梅德特公司总资产为9083.6亿美元，较上季度持平[7] - 2024年1月26日，梅德特公司股东权益为5199.6亿美元，较上季度增长0.6%[8] - 2024年1月26日，梅德特公司现金及现金等价物为162.3亿美元，较上季度减少56.8%[10] - 2024年1月26日，梅德特公司经营活动产生的净现金流为401亿美元，较上年同期增长12.2%[10] 业务表现 - 公司主要收入来源于基于设备的医疗疗法和多个领域的相关服务，包括心脏节律紊乱、神经系统疾病等[19] - 截至2024年1月26日，心脏节律与心力衰竭部门的净销售额为14.7亿美元，较去年同期增长3.6%[20] - 美国市场在2024年1月26日的三个月内，心血管部门的净销售额为13.73亿美元，较去年同期增长0.7%[21] 公司收购与资产 - 公司在2024年1月26日和2023年1月27日的九个月内进行了业务收购，资产和负债按其公允价值记录和合并[25] - 2024年1月26日，公司收购的资产主要包括6.6亿美元的商誉和3亿美元的研发资产[31] - 公司在2024年1月26日和2023年1月27日的九个月内，与业务收购相关的非现金计算的未来支付为7,300万美元[31] 财务风险管理 - 公司使用衍生工具和外币计价债务管理汇率和利率变化对财务报表的影响[62] - 公司使用外汇远期合同作为现金流量套期保值工具，用于管理未来以外币计价的现金流量的波动性[63] - 公司的现金流量套期保值将在未来三年内到期，截至2024年1月26日和2023年4月28日，公司分别有1.67亿美元和9300万美元的未实现收益[65] 公司股权及其他 - Medtronic plc在2024年1月26日的基本每股收益为0.99美元，较去年同期增长了7.6%[87] - Medtronic plc在2024年1月26日的股权报酬费用为85百万美元，较去年同期增长了4.9%[88] - Medtronic plc在2024年1月26日的退休福利计划中，美国和非美国的服务成本分别为15百万美元和10百万美元[90]

8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is actively enrolling patients in the BACKBEAT pivotal study of AVIM therapy in hypertensive pacemaker patients NEW HOPE, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patie ...